Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Tanya Barauskas DorffYosuke HirasawaJared AcobaIan PaganoDavid TamuraSumanta Kumar PalMinlu ZhangRebecca WaitzAbhilash DhalWinston HaynesJohn ShonMark ScholzHideki FuruyaOwen T M ChanJeffrey HuangCharles J RosserPublished in: Journal for immunotherapy of cancer (2022)
NCT03024216.